Randomized controlled trialHuman
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
The New England journal of medicine, 2016 Jul 28. Marso SP, Daniels GH, Brown-Frandsen K and 14 others.
Study type
Randomized controlled trial
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2016 Jul 28
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AgedCardiovascular DiseasesDiabetes Mellitus, Type 2Double-Blind MethodFemaleGastrointestinal DiseasesHumansHypoglycemic AgentsLiraglutideMaleMiddle AgedMyocardial Infarction
Other papers on Liraglutide
Randomized controlled trial · 2015
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Randomized controlled trial · 2013Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page